Stock looks poised for an upward move. It would need to tripple to be valued at current cash and tangibles. Factor in the patents, nols, phase II test results, in play to be acquired, it's probably one of the best reward to risks plays in the small cap bio sector. I put a 3-6 buyout depending on the data released on results. I might be low on the buyout to??
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.